• News
  • BioTech

Regen BioPharma files FDA application for anemia drug

Regen BioPharma, a wholly owned subsidiary of San Diego-based Bio-Matrix Scientific Group Inc. (PNK: BMSN), announced Tuesday the filing of an Investigational New Drug application with the Food and Drug Administration to initiate clinical trials assessing the company's HemaXellerate I stem cell drug in patients with drug-refractory aplastic anemia.

HemaXellerate I is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.

If the clinical trial is successful, the company plans to expand use of HemaXellerate I to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market.

This market is substantial in size and currently includes drugs such as Neupogen, Neulasta, Leukine and Revolade.


La Jolla Pharmaceutical receives patent for pectin composition

Tandem Diabetes Care acquires ownership of 23 patents

Isis Pharma shares rise on Kynamro approval

User Response
0 UserComments

Bio-Matrix Scientific Group

Company Website

1649 Dartmouth
Chula Vista, CA 91913

Bio-Matrix Scientific Group Executive(s):

David Koos

  • Chairman, Chief Executive Officer, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
NAICS - 423450 - Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers